A common type of meningitis is caused by a bacterium called Neisseria meningitidis, meningococcal disease can be quite serious. Most cases of meningococcal disease are caused by a single type of serogroup of this bacterium. In fact, there are several different types of meningococcal disease, with A, B, C, and D being the most common. The bacteria are spread through close contact and through cerebrospinal fluid.
It is transmitted by direct contact with the secretions of an infected person. Infected people may transmit the disease to others by coughing or sneezing directly into a person’s mouth, kissing someone on the mouth, sharing a glass, or sharing a cup. However, even healthy people can transmit the disease through casual contact or by breathing air from an infected person. If you are in contact with an infected person, you should get treatment immediately.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/4913
Because of the difficulty in recognizing meningococcal disease in its early stages, symptoms can be confused with other illnesses. A doctor will examine your child for fever, stiff neck, or other symptoms. He or she will also look for signs of meningitis in the child’s reflexes. Since meningococcal disease can spread through direct contact, it’s best to see a physician immediately if you suspect your child is suffering from any of these symptoms.
The global meningococcal disease treatment market is estimated to be valued at US$ 3,754.1 million in 2021 and is expected to exhibit a CAGR of 12.6% over the forecast period (2021-2028).
Growing number of drug approval is expected to drive the market growth over the forecast period
For instance, in 2018, GlaxoSmithKline Plc., a pharmaceutical company has received breakthrough therapy designation from the U.S. Food and Drug Administration for Bexsero for prevention of invasive meningococcal disease in children 2-10 years of age.
Furthermore, in 2016, Pfizer Inc., a pharmaceutical company, announced that European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for its TRUMENBA (Meningococcal Group B Vaccine) for review.
TRUMENBA is developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older.
Increasing number of people travelling to sub-Saharan Africa is expected to propel growth of the global meningococcal disease market
Significant number of people travelling to sub-Saharan Africa is expected to propel growth of the global meningococcal vaccines market over the forecast period. According to World Economic Forum’s, 2018 report, 37.4 million tourist arrivals were recorded in Sub-Saharan Africa in 2017.
Additionally, recommendation of various regulatory bodies for meningococcal vaccination is also expected to support growth of the market. For instance, the Centers for Disease Control and Prevention recommends meningococcal vaccines for preteens, teens, and other people.
Global Meningococcal Disease Treatment Market– Impact of Coronavirus (Covid-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in more than 114 million infected individuals worldwide as of March 2nd 2021.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drugs from one place to another.
Furthermore, players involved in the global meningococcal disease treatment market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing of product due to irregularities in transportation facility. Moreover, distributors are experiencing irregular demand for products from the retailers due to increasing number of patients suffering from COVID-19 and other life threatening disorders.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/4913
Global Meningococcal Disease Treatment Market Restraint
High cost of meningococcal vaccination and low coverage of the same are expected to hinder the growth of the global meningococcal vaccines market
Moreover, meningococcal vaccination is optional in several countries, which is also expected to limit the market growth.
Major players operating in the global meningococcal disease treatment market include GlaxoSmithKline Plc., Novartis AG, Sanofi Pasteur Inc., Wockhardt Ltd., Kent Pharmaceuticals, Stravencon Limited., F. Hoffmann-La Roche Ltd., Athlone Laboratories, and Pfizer Inc.
Reasons to buy this Meningococcal Disease Treatment Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Meningococcal Disease Treatment Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Meningococcal Disease Treatment Market
◘ Leading company profiles reveal details of key Meningococcal Disease Treatment Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Meningococcal Disease Treatment Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Meningococcal Disease Treatment Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Meningococcal Disease Treatment Market are also given.
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/4913
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Meningococcal Disease Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Meningococcal Disease Treatment Industry Impact
Chapter 2 Global Meningococcal Disease Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Meningococcal Disease Treatment (Volume and Value) by Type
2.3 Global Meningococcal Disease Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Meningococcal Disease Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Meningococcal Disease Treatment Market Analysis
Chapter 6 East Asia Meningococcal Disease Treatment Market Analysis
Chapter 7 Europe Meningococcal Disease Treatment Market Analysis
Chapter 8 South Asia Meningococcal Disease Treatment Market Analysis
Chapter 9 Southeast Asia Meningococcal Disease Treatment Market Analysis
Chapter 10 Middle East Meningococcal Disease Treatment Market Analysis
Chapter 11 Africa Meningococcal Disease Treatment Market Analysis
Chapter 12 Oceania Meningococcal Disease Treatment Market Analysis
Chapter 13 South America Meningococcal Disease Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Meningococcal Disease Treatment Business
Chapter 15 Global Meningococcal Disease Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027